JP7260723B2 - ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン - Google Patents

ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン Download PDF

Info

Publication number
JP7260723B2
JP7260723B2 JP2022563041A JP2022563041A JP7260723B2 JP 7260723 B2 JP7260723 B2 JP 7260723B2 JP 2022563041 A JP2022563041 A JP 2022563041A JP 2022563041 A JP2022563041 A JP 2022563041A JP 7260723 B2 JP7260723 B2 JP 7260723B2
Authority
JP
Japan
Prior art keywords
compound
cancer
her2
pharmaceutically acceptable
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512343A (ja
Inventor
ヴィルディング，ビルギット
ブーセ，ディートリヒ
エンゲルハルト，ハーラルト
フックス，ユリアン
ノイミュラー，ラルフ
ペトロンスキ，マルク
シャルン，ディルク
トロイ，マティアス
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023512343A publication Critical patent/JP2023512343A/ja
Priority to JP2023062141A priority Critical patent/JP2023085489A/ja
Application granted granted Critical
Publication of JP7260723B2 publication Critical patent/JP7260723B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022563041A 2020-04-24 2021-04-07 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン Active JP7260723B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023062141A JP2023085489A (ja) 2020-04-24 2023-04-06 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171221.3 2020-04-24
EP20171221 2020-04-24
PCT/EP2021/059015 WO2021213800A1 (en) 2020-04-24 2021-04-07 [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062141A Division JP2023085489A (ja) 2020-04-24 2023-04-06 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン

Publications (2)

Publication Number Publication Date
JP2023512343A JP2023512343A (ja) 2023-03-24
JP7260723B2 true JP7260723B2 (ja) 2023-04-18

Family

ID=70470818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563041A Active JP7260723B2 (ja) 2020-04-24 2021-04-07 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP2023062141A Pending JP2023085489A (ja) 2020-04-24 2023-04-06 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023062141A Pending JP2023085489A (ja) 2020-04-24 2023-04-06 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン

Country Status (33)

Country Link
US (3) US11608343B2 (enExample)
EP (2) EP4139309B9 (enExample)
JP (2) JP7260723B2 (enExample)
KR (2) KR102759974B1 (enExample)
CN (13) CN118388490A (enExample)
AR (1) AR121779A1 (enExample)
AU (1) AU2021260721A1 (enExample)
CA (1) CA3173602A1 (enExample)
CL (1) CL2022002579A1 (enExample)
CO (1) CO2022015054A2 (enExample)
CR (1) CR20220537A (enExample)
DK (1) DK4139309T5 (enExample)
DO (1) DOP2022000189A (enExample)
EC (1) ECSP22072777A (enExample)
ES (1) ES3013860T3 (enExample)
FI (1) FI4139309T3 (enExample)
HR (1) HRP20250426T1 (enExample)
HU (1) HUE070805T2 (enExample)
IL (2) IL297490B2 (enExample)
JO (1) JOP20220271A1 (enExample)
LT (1) LT4139309T (enExample)
MA (1) MA59373B1 (enExample)
MX (1) MX2022013223A (enExample)
PE (1) PE20230827A1 (enExample)
PH (1) PH12022552745A1 (enExample)
PL (1) PL4139309T3 (enExample)
PT (1) PT4139309T (enExample)
RS (1) RS66557B1 (enExample)
SI (1) SI4139309T1 (enExample)
SM (1) SMT202500164T1 (enExample)
TW (1) TWI913256B (enExample)
UA (1) UA130588C2 (enExample)
WO (1) WO2021213800A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119390683A (zh) 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物
US20230126204A1 (en) * 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022266458A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-heterocycloalkyl-quinazoline derivatives and uses thereof
JP7511097B1 (ja) 2021-06-26 2024-07-04 アレイ バイオファーマ インコーポレイテッド Ｈｅｒ２変異阻害薬
US20250136595A1 (en) * 2022-02-09 2025-05-01 Enliven Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
JP2025509995A (ja) 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
KR102854653B1 (ko) * 2022-04-05 2025-09-04 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2024027695A1 (zh) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 作为her2抑制剂的化合物
US20240132521A1 (en) 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
KR20250133319A (ko) 2022-12-22 2025-09-05 베링거 인겔하임 인터내셔날 게엠베하 Her2 억제제의 결정형
MX2025007174A (es) 2022-12-22 2025-07-01 Boehringer Ingelheim Int Dispersion solida de un inhibidor de her2
CN120456906A (zh) 2022-12-22 2025-08-08 勃林格殷格翰国际有限公司 Her2抑制剂的固体分散体的给药安排方案
AU2024247020A1 (en) 2023-03-29 2025-10-30 Boehringer Ingelheim International Gmbh Dosing schedule of a her2 inhibitor
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
WO2024246114A1 (en) 2023-05-31 2024-12-05 Boehringer Ingelheim International Gmbh Survivin as a biomarker for predicting the responsiveness of cancer treatment
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
KR20260059568A (ko) 2023-07-28 2026-04-30 베링거 인겔하임 인터내셔날 게엠베하 Her2 억제제의 제조 방법
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN121729231A (zh) * 2023-09-06 2026-03-24 勃林格殷格翰国际有限公司 用HER2抑制剂和CYP3A和/或P-gp调节剂进行的癌症治疗
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
US20250205238A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
US20250228858A1 (en) 2023-12-20 2025-07-17 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025210042A1 (en) * 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025257149A1 (en) 2024-06-11 2025-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of zongertinib a her2 tyrosine kinase inhibitor
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026007878A1 (zh) * 2024-07-01 2026-01-08 北京鞍石生物科技股份有限公司 稠环化合物及其制备方法和应用
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026027757A1 (en) 2024-08-02 2026-02-05 Boehringer Ingelheim International Gmbh Treatment of cancer with metastases in the central nervous system
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026077844A1 (en) 2024-10-07 2026-04-16 Boehringer Ingelheim International Gmbh Solid dispersions having stabilized emulsion particles
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059257A2 (en) 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2019042409A1 (zh) 2017-09-01 2019-03-07 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
WO2021156178A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021156180A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL161908A0 (en) 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
WO2007059217A2 (en) * 2005-11-16 2007-05-24 Lonnie Lehrer Automobile propulsion system
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
MY186839A (en) 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
JP6863901B2 (ja) 2015-05-13 2021-04-28 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
EP3676267A4 (en) 2017-08-31 2021-04-14 Dana Farber Cancer Institute, Inc. EGFR AND / OR HER2 INHIBITORS AND METHODS OF USE
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059257A2 (en) 2005-11-15 2007-05-24 Array Biopharma Inc. N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2019042409A1 (zh) 2017-09-01 2019-03-07 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
WO2021156178A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021156180A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors

Also Published As

Publication number Publication date
TWI913256B (zh) 2026-02-01
ECSP22072777A (es) 2022-10-31
PE20230827A1 (es) 2023-05-19
AU2021260721A1 (en) 2022-09-15
FI4139309T3 (fi) 2025-03-04
CN118388493A (zh) 2024-07-26
CN118388491A (zh) 2024-07-26
CN118388494A (zh) 2024-07-26
CA3173602A1 (en) 2021-10-28
CR20220537A (es) 2022-12-06
CN118388495A (zh) 2024-07-26
MX2022013223A (es) 2022-11-14
CN118307543A (zh) 2024-07-09
PT4139309T (pt) 2025-02-17
US20250122204A1 (en) 2025-04-17
KR102759974B1 (ko) 2025-01-24
DK4139309T3 (da) 2025-04-28
UA130588C2 (uk) 2026-03-25
CN118307544A (zh) 2024-07-09
SMT202500164T1 (it) 2025-05-12
IL320477A (en) 2025-06-01
US20230374021A1 (en) 2023-11-23
CO2022015054A2 (es) 2023-02-16
TW202206432A (zh) 2022-02-16
MA59373B1 (fr) 2025-02-28
EP4139309B1 (en) 2025-01-29
IL297490B2 (en) 2025-10-01
AR121779A1 (es) 2022-07-06
WO2021213800A1 (en) 2021-10-28
CN118388489A (zh) 2024-07-26
SI4139309T1 (sl) 2025-03-31
KR20230005263A (ko) 2023-01-09
US20210332054A1 (en) 2021-10-28
DK4139309T5 (da) 2025-10-27
KR20250016507A (ko) 2025-02-03
JP2023512343A (ja) 2023-03-24
JOP20220271A1 (ar) 2021-10-28
BR112022021514A2 (pt) 2023-01-24
DOP2022000189A (es) 2022-09-30
LT4139309T (lt) 2025-02-25
RS66557B1 (sr) 2025-03-31
US11608343B2 (en) 2023-03-21
IL297490A (en) 2022-12-01
ES3013860T3 (en) 2025-04-15
CN115485277A (zh) 2022-12-16
HUE070805T2 (hu) 2025-07-28
CN118388492A (zh) 2024-07-26
EP4566611A2 (en) 2025-06-11
CN118388488A (zh) 2024-07-26
EP4139309B9 (en) 2025-09-10
EP4566611A3 (en) 2025-09-10
IL297490B1 (en) 2025-06-01
HRP20250426T1 (hr) 2025-06-06
PL4139309T3 (pl) 2025-05-05
CN118619956A (zh) 2024-09-10
PH12022552745A1 (en) 2024-03-25
CN118388487A (zh) 2024-07-26
ES3013860T9 (en) 2025-10-28
CN118388490A (zh) 2024-07-26
JP2023085489A (ja) 2023-06-20
CN115485277B (zh) 2024-05-14
CL2022002579A1 (es) 2023-05-19
EP4139309A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
KR102759974B1 (ko) HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘
JP7626774B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
EP4100409B1 (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40122799A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
EA047617B1 (ru) [1,3]ДИАЗИНО[5,4-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ HER2
BR112022021514B1 (pt) [1,3]diazino[5,4-d]pirimidinas como inibidores de her2
HK40081106B (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40081106A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221110

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230406

R150 Certificate of patent or registration of utility model

Ref document number: 7260723

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250